The MEK inhibitor trametinib incurs mitochondrial injury and induces innate immune responses in the mouse heart
Kelsey H. Fisher‐Wellman, Richard D. Lutze, Logan G. Kirkland, Ju Youn Beak, Mansi Goyal, Raghu Nagalingam, Samantha M. Morrissey, Peyton B. Sandroni, Wei Huang, Julian D. Bailon, Melissa A. Schroder, Lars A. Albrecht, Ethelyn Ofei, Andrew L. Chin, Thomas D. Green, , Brian C. Jensen
This study shows trametinib causes mitochondrial injury and innate immune activation in mouse hearts, leading to cardiomyopathy and heart failure.
Science Advances · Jul 10, 2026Peer-reviewedPhysiology